Nan Fung Group Holdings’s Entrada Therapeutics TRDA Stock Holding History

Nan Fung Group Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$361K	Hold	49,082	–	–	0.27%	24
2026 Q1	$619K	Hold	49,082	–	–	0.51%	21
2025 Q4	$505K	Hold	49,082	–	–	0.45%	23
2025 Q3	$285K	Hold	49,082	–	–	0.48%	21
2025 Q2	$330K	Hold	49,082	–	–	0.52%	18
2025 Q1	$444K	Hold	49,082	–	–	0.36%	31
2024 Q4	$849K	Hold	49,082	–	–	0.73%	26
2024 Q3	$784K	Hold	49,082	–	–	0.68%	25
2024 Q2	$699K	Hold	49,082	–	–	0.75%	25
2024 Q1	$695K	Hold	49,082	–	–	0.64%	28
2023 Q4	$741K	Hold	49,082	–	–	0.46%	24
2023 Q3	$775K	Hold	49,082	–	–	0.63%	21
2023 Q2	$743K	Sell	49,082 -24,500	-33%	-$338K	0.47%	24
2023 Q1	$1.07M	Hold	73,582	–	–	0.73%	23
2022 Q4	$995K	Sell	73,582 -68,011	-48%	-$1.19M	0.69%	20
2022 Q3	$2.23M	Sell	141,593 -31,989	-18%	-$406K	1.42%	13
2022 Q2	$2.11M	Hold	173,582	–	–	1.45%	15
2022 Q1	$1.63M	Buy	+173,582	New	+$1.86M	0.77%	17

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Nan Fung Group Holdings's TRDA Position: Q2 2026 in Review

Nan Fung Group Holdings held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 49,082 shares worth $361K. The position accounts for 0.27% of the portfolio, ranked #24.

Nan Fung Group Holdings first reported a position in TRDA in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.23M in Q3 2022. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Nan Fung Group Holdings held 49,082 shares of Entrada Therapeutics worth $361K as of Q2 2026.
Nan Fung Group Holdings left its Entrada Therapeutics share count unchanged in Q2 2026.
Entrada Therapeutics made up 0.27% of Nan Fung Group Holdings's portfolio in Q2 2026, its #24 holding.
Nan Fung Group Holdings first reported a position in Entrada Therapeutics in Q1 2022 and has held it in 18 quarters since.
Nan Fung Group Holdings's Entrada Therapeutics position peaked at $2.23M in Q3 2022.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Nan Fung Group Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.